“We are honored to have Dr. Chittima Sirijerachai agree to become a PI for Rich Pharmaceuticals” said Ben Chang, Chief Executive Officer of the Company. “We greatly value her expertise and guidance in our planned clinical trials. In addition, we continue to aggressively push ahead with our AML clinical plans and with Therinova’s clinical research expertise in oncology, we are confident in our regulatory approval strategy,” continued Ben Chang.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.